PeptideStack

Tesamorelin

Discover the science behind Tesamorelin, an FDA-approved peptide for targeted fat loss. Explore Tesamorelin benefits, mechanisms, and clinical research.

FDA Approvedweight losshealinggrowth hormonefat burningfda approved

Last updated:

Administration
subcutaneous
Origin
Synthetic (GHRH Analog)

Overview

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to secrete endogenous growth hormone. As an FDA-approved medication marketed under the brand name Egrifta, this peptide is primarily utilized to reduce excess visceral adipose tissue in patients with HIV-associated lipodystrophy. The Tesamorelin peptide matters because it provides targeted fat loss without significantly altering glucose metabolism, offering a unique therapeutic profile compared to direct human growth hormone administration.

Potential Benefits

  • Visceral Fat Reduction: Clinical trials demonstrate that Tesamorelin significantly reduces visceral adipose tissue in patients with HIV-associated lipodystrophy Dhillon S, 2011.
  • Improved Fat Quality: Research indicates that the peptide improves overall fat quality and density independent of changes in total fat quantity Lake JE et al., 2021.
  • Liver Fat Reduction: Phase 2 clinical trials have investigated its efficacy in reducing hepatic fat in patients with nonalcoholic fatty liver disease (NAFLD) NCT03375788.
  • Muscle Preservation: By stimulating natural growth hormone release, it may help preserve lean muscle mass, prompting studies into its effects on physical function NCT06554717.
  • Favorable Metabolic Profile: Unlike direct growth hormone therapy, Tesamorelin maintains a more stable glucose profile and reduces the risk of severe insulin resistance Spooner LM et al., 2012.

Where to Buy Tesamorelin

Pinnacle Peptide Labs

View →

Ascension Peptides

View →

Licensed Peptides

View →

These vendors are listed for research reference only. PeptideStack does not endorse, verify, or receive compensation from any vendor. Always verify purity and legitimacy independently.

Side Effects

Common side effects:

  • Injection site reactions (erythema, pruritus, pain)
  • Arthralgia (joint pain) and myalgia (muscle pain)
  • Peripheral edema (swelling in the extremities)
  • Mild, transient increases in blood glucose levels

Rare or serious side effects:

  • Hypersensitivity reactions or anaphylaxis
  • Development of neutralizing antibodies
  • Increased risk of malignancies associated with elevated IGF-1
  • Significant glucose intolerance or diabetes exacerbation

Tesamorelin is FDA-approved but should only be used under medical supervision. Consult a qualified healthcare provider before use.

Mechanism of Action

Receptor activation drives the primary mechanism of the Tesamorelin peptide. Upon subcutaneous administration, it binds to growth hormone-releasing hormone (GHRH) receptors located in the anterior pituitary gland. This binding stimulates the synthesis and pulsatile release of endogenous growth hormone (GH) into the systemic circulation, mimicking the body's natural physiological rhythms Wang Y et al., 2009.

Lipolytic signaling occurs as a downstream effect of elevated circulating growth hormone levels. The increased GH binds to specific receptors on adipocytes, particularly in visceral fat deposits, triggering lipolysis and reducing triglyceride accumulation. Furthermore, this pathway increases insulin-like growth factor 1 (IGF-1) levels without causing the severe negative feedback loop often associated with exogenous recombinant human growth hormone Grunfeld C et al., 2011.

Origin & History

Synthetic development of Tesamorelin was pioneered by Theratechnologies Inc. to create a more stable and effective GHRH analogue. Researchers modified the natural 44-amino acid sequence of human GHRH by adding a trans-3-hexenoic acid group to the N-terminus, significantly increasing its resistance to degradation by dipeptidyl peptidase-4 (DPP-4) and extending its half-life. This structural enhancement allowed for practical once-daily subcutaneous dosing.

Regulatory approval marked a major milestone when the FDA approved the peptide under the brand name Egrifta in 2010. It was specifically authorized for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy FDA Label. Since its approval, ongoing clinical trials have continued to explore Tesamorelin benefits for other metabolic conditions, including nonalcoholic fatty liver disease and COPD-related muscle wasting NCT01388920.

Frequently Asked Questions

Research & Resources

FDA Prescribing Information

PubMed Studies

View all studies on PubMed →

Clinical Trials

Data last updated: April 3, 2026

Related Peptides

Ipamorelin

Research Only

Discover the science behind the Ipamorelin peptide. Explore its research-backed benefits for bone density, body composition, and gastrointestinal function.

Sermorelin

Research Only

Explore Sermorelin, a synthetic growth hormone secretagogue peptide. Discover Sermorelin benefits for anti-aging, sleep, and natural HGH production.

sleep aid